I think you're taking a very short term view of a sector, pharmaceuticals, that is of a very long term nature. The sort of acquisitions and partnerships needed to provide drug development candidates do not depend on stock price, but on the sort of cash used up in a buyback. You may have an understanding of market psychology, but I don't think you have any understanding of the underlying pharmaceutical business. For the continuing success of ABBV, buyback of stock is more likely a negative than a positive. If management is more concerned with short term share price, they are not competent to manage a pharmaceutical company.